Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of ...

Novo Nordisk has been on the hunt for differentiated ... a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule that blocks ...

Novo Nordisk will pay Lexicon Pharmaceuticals $75 million up front to license its experimental obesity treatment. The news sent penny stock Lexicon into the stratosphere. Lexicon is taking a ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Novo Nordisk has signed another obesity ... The Danish drugmaker is licensing a drug called LX9851 from Lexicon Pharmaceuticals, according to an announcement Friday. Lexicon could receive up ...

Lexicon Pharmaceuticals secured a licensing deal with Novo Nordisk for LX9851, with potential payments totaling $1 billion-plus royalties. Preclinical data show that LX9851 enhances weight loss ...

(Reuters) -Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...